Ascletis Received IND Approval and Management Outlook of 2019 and Beyond
2019-08-05Ascletis to Attend Goldman Sachs China Healthcare Corporate Day 2019
2019-06-243-V Biosciences Commences Dosing in Phase 2 Clinical Study of the FASN Inhibitor TVB-2640 in Patients with NASH
2019-05-01Ganovo is Eligible for the Basic Medical Insurance of Zhejiang Province - Reimbursement-by-disease
2019-04-15Ascletis Appoints Former MSD Global Vice President Dr. Zhengqing Li as Chief Medical Officer and President of R&D Greater China
2019-03-01
